| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 28 May 2025 | 7 May 2025 |
| Granules India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 inter alia to consider and approve the audited financial results for the FY ended March 31 2025 and recommendation of final dividend if any. Outcome of the Board Meeting (As Per BSE Announcement Dated on :28.05.2025) | ||
| Board Meeting | 25 Mar 2025 | 25 Mar 2025 |
| Outcome of Board Meeting | ||
| Board Meeting | 21 Feb 2025 | 21 Feb 2025 |
| Outcome of the Board Meeting | ||
| Board Meeting | 24 Jan 2025 | 8 Jan 2025 |
| GRANULES INDIA LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve Unaudited Financial results for the quarter and nine months ended on December 31 2024. Un-Audited Financial Results for the Quarter & Nine-Months ended on December 31, 2024. (As Per BSE Announcement dated on 24.01.2025) | ||
| Board Meeting | 6 Nov 2024 | 17 Oct 2024 |
| GRANULES INDIA LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2024 inter alia to consider and approve the unaudited Consolidated and Standalone Financial Results of the Company for the Second Quarter and half year ended September 30 2024. Unaudited Financial Results for the second quarter and half year ended on September 30, 2024. (As Per BSE Announcement Dated on 06.11.2024) | ||
| Board Meeting | 30 Jul 2024 | 15 Jul 2024 |
| GRANULES INDIA LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2024 inter alia to consider and approve the un-audited financial results for the quarter ended on June 30 2024. Un-audited Financial Results for the Quarter ended June 30, 2024 (As Per BSE Announcement dated on 30.07.2024) | ||
The firm’s net debt fell by ₹136 crore to ₹706.1 crore, with a comfortable net debt-to-EBITDA at 0.75x
The pharma company caters to various international markets, reinforcing its position as a key player in the pharmaceutical industry.
Granules India, maintaining that it fully intends to respond in the time period allowed, as well as requesting a meeting with the FDA to show progress made in compliance, has taken care to make this clear as well.
The inspection covered Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for oncology and non-oncology segments, underscoring the plant’s adherence to high manufacturing standards.
Bupropion hydrochloride is widely prescribed for treating major depressive disorder (MDD) and preventing seasonal affective disorder (SAD).
The USFDA has also noted a repeat observation from the company's January 2023 inspection.
Glycopyrrolate Oral Solution is an anticholinergic medication used to treat pediatric patients aged 3 to 16 years with neurological conditions that cause drooling.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
